{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:25:53Z","timestamp":1794349553909,"version":"4.9.0"},"reference-count":97,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T00:00:00Z","timestamp":1789084800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82170535"],"award-info":[{"award-number":["82170535"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.isci.2026.117684","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T00:05:49Z","timestamp":1790121949000},"page":"117684","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Viral persistence and immune dysfunction in chronic hepatitis B: Mechanisms of post-treatment antigen asynchrony"],"prefix":"10.1016","volume":"29","author":[{"given":"Shi-Yu","family":"Du","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bai","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4626-9828","authenticated-orcid":false,"given":"Qing-Long","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2026.117684_bib2","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.jhep.2025.03.018","article-title":"EASL Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"83","year":"2025","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib3","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1016\/j.jhep.2018.10.014","article-title":"HBsAg seroclearance further reduces hepatocellular carcinoma risk after complete viral suppression with nucleos(t)ide analogues","volume":"70","author":"Yip","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib4","doi-asserted-by":"crossref","first-page":"2214","DOI":"10.1136\/gutjnl-2019-320015","article-title":"Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study","volume":"69","author":"Kim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib5","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1007\/s10620-014-3486-7","article-title":"Seven-year efficacy and safety of treatment with tenofovir disoproxil fumarate for chronic hepatitis B virus infection","volume":"60","author":"Buti","year":"2015","journal-title":"Dig. Dis. Sci."},{"key":"10.1016\/j.isci.2026.117684_bib6","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/hepr.14129","article-title":"Factors associated with low hepatitis B surface antigen levels in chronic hepatitis B patients treated with nucleot(s)ide analogs","volume":"55","author":"Suzuki","year":"2024","journal-title":"Hepatol. Res."},{"key":"10.1016\/j.isci.2026.117684_bib7","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jfma.2023.01.004","article-title":"Trend patterns of HBsAg kinetics in chronic hepatitis B patients during nucleos(t)ide analogue therapy based on ARMA models","volume":"122","author":"Yu","year":"2023","journal-title":"J. Formos. Med. Assoc."},{"key":"10.1016\/j.isci.2026.117684_bib8","article-title":"Host immunity and HBV S gene mutation in HBsAg-negative HBV-infected patients","volume":"14","author":"Liu","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib9","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/0016-5085(92)91191-6","article-title":"Serum and liver hepatitis B virus DNA in chronic hepatitis B after sustained loss of surface antigen","volume":"103","author":"Kuhns","year":"1992","journal-title":"Gastroenterology"},{"key":"10.1016\/j.isci.2026.117684_bib10","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.coviro.2014.04.005","article-title":"Nucleoside\/nucleotide analog inhibitors of hepatitis B virus polymerase: mechanism of action and resistance","volume":"8","author":"Men\u00e9ndez-Arias","year":"2014","journal-title":"Curr. Opin. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib11","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1016\/S0140-6736(22)01468-4","article-title":"Hepatitis B","volume":"401","author":"Jeng","year":"2023","journal-title":"Lancet"},{"key":"10.1016\/j.isci.2026.117684_bib12","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40265-023-01843-2","article-title":"Emerging Therapies for Chronic Hepatitis B and the Potential for a Functional Cure","volume":"83","author":"Chang","year":"2023","journal-title":"Drugs"},{"key":"10.1016\/j.isci.2026.117684_bib13","doi-asserted-by":"crossref","first-page":"9913","DOI":"10.1073\/pnas.0504273102","article-title":"Interferon prevents formation of replication-competent hepatitis B virus RNA-containing nucleocapsids","volume":"102","author":"Wieland","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.isci.2026.117684_bib14","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1038\/s41401-021-00765-7","article-title":"IFN-\u03b1 inhibits HBV transcription and replication by promoting HDAC3-mediated de-2-hydroxyisobutyrylation of histone H4K8 on HBV cccDNA minichromosome in liver","volume":"43","author":"Zhao","year":"2022","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.isci.2026.117684_bib15","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1172\/JCI58847","article-title":"IFN-\u03b1 inhibits HBV transcription and replication in cell culture and in humanized mice by targeting the epigenetic regulation of the nuclear cccDNA minichromosome","volume":"122","author":"Belloni","year":"2012","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117684_bib16","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1126\/science.1243462","article-title":"Specific and nonhepatotoxic degradation of nuclear hepatitis B virus cccDNA","volume":"343","author":"Lucifora","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.isci.2026.117684_bib17","article-title":"Interferon and interferon-stimulated genes in HBV treatment","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib18","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1097\/HEP.0000000000000524","article-title":"Single-cell RNA sequencing reveals the immunoregulatory roles of PegIFN-\u03b1 in patients with chronic hepatitis B","volume":"79","author":"Jiang","year":"2024","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib19","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.jhep.2024.06.033","article-title":"Varied immune responses of HBV-specific B cells in patients undergoing pegylated interferon-alpha treatment for chronic hepatitis B","volume":"81","author":"Zhang","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib20","doi-asserted-by":"crossref","first-page":"892","DOI":"10.1007\/s12072-024-10648-8","article-title":"Predictors of HBsAg seroclearance in patients with chronic HBV infection treated with pegylated interferon-\u03b1: a systematic review and meta-analysis","volume":"18","author":"Jiang","year":"2024","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.isci.2026.117684_bib21","doi-asserted-by":"crossref","first-page":"1972","DOI":"10.1136\/gutjnl-2015-309809","article-title":"HBV cccDNA: viral persistence reservoir and key obstacle for a cure of chronic hepatitis B","volume":"64","author":"Nassal","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib22","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1016\/j.jhep.2021.05.013","article-title":"Covalently closed circular DNA: The ultimate therapeutic target for curing HBV infections","volume":"75","author":"Martinez","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib23","doi-asserted-by":"crossref","DOI":"10.3390\/v9040075","article-title":"HBV DNA Integration: Molecular Mechanisms and Clinical Implications","volume":"9","author":"Tu","year":"2017","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.117684_bib24","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1016\/j.jhep.2024.06.037","article-title":"Hepatitis B virus DNA integration: Implications for diagnostics, therapy, and outcome","volume":"81","author":"Zoulim","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib25","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1016\/j.jhep.2021.04.051","article-title":"Ubiquitous expression of HBsAg from integrated HBV DNA in patients with low viral load","volume":"75","author":"Meier","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib26","doi-asserted-by":"crossref","DOI":"10.1172\/JCI184243","article-title":"Transcription of hepatitis B surface antigen shifts from cccDNA to integrated HBV DNA during treatment","volume":"135","author":"Taddese","year":"2025","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117684_bib27","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1136\/gutjnl-2023-330577","article-title":"Spatial transcriptomics reveals a low extent of transcriptionally active hepatitis B virus integration in patients with HBsAg loss","volume":"73","author":"Yu","year":"2024","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib28","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/j.jhep.2021.07.030","article-title":"Infection courses, virological features and IFN-\u03b1 responses of HBV genotypes in cell culture and animal models","volume":"75","author":"Zhang","year":"2021","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib29","doi-asserted-by":"crossref","first-page":"514","DOI":"10.1016\/j.jhep.2010.01.014","article-title":"Hepatitis B surface antigen (HBsAg) levels in the natural history of hepatitis B virus (HBV)-infection: a European perspective","volume":"52","author":"Jaroszewicz","year":"2010","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib30","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1111\/apt.18448","article-title":"Virological and Immunological Characteristics of HBeAg-Positive Chronic Hepatitis B Patients With Low HBsAg Levels","volume":"61","author":"Chen","year":"2025","journal-title":"Aliment. Pharmacol. Ther."},{"key":"10.1016\/j.isci.2026.117684_bib31","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1002\/hep.24363","article-title":"Emergence of hepatitis B virus S gene mutants in patients experiencing hepatitis B surface antigen seroconversion after peginterferon therapy","volume":"54","author":"Hsu","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib32","doi-asserted-by":"crossref","first-page":"2823","DOI":"10.1172\/JCI137477","article-title":"When viruses collide: hepatitis B virus reactivation after hepatitis C treatment","volume":"130","author":"Balagopal","year":"2020","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117684_bib33","doi-asserted-by":"crossref","DOI":"10.3390\/v12070741","article-title":"Hepatitis C Virus and Hepatitis B Virus Co-Infection","volume":"12","author":"Shih","year":"2020","journal-title":"Viruses"},{"key":"10.1016\/j.isci.2026.117684_bib34","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aau6905","article-title":"Multifactorial heterogeneity of virus-specific T cells and association with the progression of human chronic hepatitis B infection","volume":"4","author":"Cheng","year":"2019","journal-title":"Sci. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib35","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1136\/gutjnl-2022-327202","article-title":"Phenotypic CD8 T cell profiling in chronic hepatitis B to predict HBV-specific CD8 T cell susceptibility to functional restoration in vitro","volume":"72","author":"Rossi","year":"2023","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib36","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1038\/s41577-024-01097-3","article-title":"Beyond exhaustion: the unique characteristics of CD8(+) T cell dysfunction in chronic HBV infection","volume":"24","author":"Thimme","year":"2024","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib37","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1097\/HEP.0000000000001549","article-title":"AASLD ISDA Practice Guideline on treatment of chronic hepatitis B","volume":"83","author":"Ghany","year":"2026","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib38","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1002\/hep.30417","article-title":"Entecavir and Peginterferon Alfa-2a in Adults With Hepatitis B e Antigen-Positive Immune-Tolerant Chronic Hepatitis B Virus Infection","volume":"69","author":"Feld","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib39","doi-asserted-by":"crossref","DOI":"10.1002\/eji.202451046","article-title":"Restoration of CD3(+)CD56(+) NKT-like cell function by TIGIT blockade in inactive carrier and immune tolerant patients of chronic hepatitis B virus infection","volume":"54","author":"Yu","year":"2024","journal-title":"Eur. J. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib40","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1007\/s12072-025-10846-y","article-title":"Single-cell transcriptomic profiling reveals dysregulation of B-cell subset function in patients with chronic hepatitis B","volume":"19","author":"Li","year":"2025","journal-title":"Hepatol. Int."},{"key":"10.1016\/j.isci.2026.117684_bib41","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1474853","article-title":"Monocyte-derived Galectin-9 and PD-L1 differentially impair adaptive and innate immune response in chronic HBV infection and their expression remain unaltered after antiviral therapy","volume":"15","author":"Dey","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib42","doi-asserted-by":"crossref","first-page":"10395","DOI":"10.3748\/wjg.v20.i30.10395","article-title":"Natural history of chronic hepatitis B: phases in a complex relationship","volume":"20","author":"Croagh","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2026.117684_bib43","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jhep.2022.02.016","article-title":"Multi-parametric analysis of human livers reveals variation in intrahepatic inflammation across phases of chronic hepatitis B infection","volume":"77","author":"Montanari","year":"2022","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib44","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1111\/liv.16032","article-title":"Differential HBV replicative markers and covalently closed circular DNA transcription in immune-active chronic hepatitis B with and without HBeAg","volume":"44","author":"Kim","year":"2024","journal-title":"Liver Int."},{"key":"10.1016\/j.isci.2026.117684_bib45","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1002\/jmv.27545","article-title":"Combining the HBcrAg decline and HBV mutations predicts spontaneous HBeAg seroconversion in chronic hepatitis B patients during the immune clearance phase","volume":"94","author":"Xie","year":"2022","journal-title":"J. Med. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib46","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1038\/s41598-022-08457-w","article-title":"Natural antibody IgG levels are associated with HBeAg-positivity and seroconversion in chronic hepatitis B patients treated with entecavir","volume":"12","author":"Choi","year":"2022","journal-title":"Sci. Rep."},{"key":"10.1016\/j.isci.2026.117684_bib47","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.jhep.2024.02.017","article-title":"Single-cell landscape of functionally cured chronic hepatitis B patients reveals activation of innate and altered CD4-CTL-driven adaptive immunity","volume":"81","author":"Narmada","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib48","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1136\/gutjnl-2011-301073","article-title":"Innate and adaptive immune responses in chronic hepatitis B virus infections: towards restoration of immune control of viral infection","volume":"61","author":"Bertoletti","year":"2012","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib49","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/j.coph.2016.07.013","article-title":"Chronic hepatitis B: immune pathogenesis and emerging immunotherapeutics","volume":"30","author":"Chang","year":"2016","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.isci.2026.117684_bib50","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1128\/JVI.01825-10","article-title":"Hepatitis B virus regulatory HBx protein binds to adaptor protein IPS-1 and inhibits the activation of beta interferon","volume":"85","author":"Kumar","year":"2011","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib51","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1000986","article-title":"Hepatitis B virus polymerase blocks pattern recognition receptor signaling via interaction with DDX3: implications for immune evasion","volume":"6","author":"Wang","year":"2010","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.isci.2026.117684_bib52","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.965018","article-title":"Toll-like receptor-mediated innate immunity orchestrates adaptive immune responses in HBV infection","volume":"13","author":"Du","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib53","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1002\/hep.30637","article-title":"Characteristics of Impaired Dendritic Cell Function in Patients With Hepatitis B Virus Infection","volume":"70","author":"Yonejima","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib54","doi-asserted-by":"crossref","first-page":"2","DOI":"10.20411\/pai.v3i1.228","article-title":"ADCC-Mediated CD56(DIM) NK Cell Responses Are Associated with Early HBsAg Clearance in Acute HBV Infection","volume":"3","author":"Yu","year":"2018","journal-title":"Pathog. Immun."},{"key":"10.1016\/j.isci.2026.117684_bib55","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2024.1427519","article-title":"Peripheral NK cell phenotypic alteration and dysfunctional state post hepatitis B subviral particles stimulation in CHB patients: evading immune surveillance","volume":"15","author":"Selim","year":"2024","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib56","article-title":"Association of HBsAg levels with differential gene expression in NK, CD8 T, and memory B cells in treated patients with chronic HBV","volume":"6","author":"Beudeker","year":"2024","journal-title":"JHEP Rep."},{"key":"10.1016\/j.isci.2026.117684_bib57","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aba6322","article-title":"Clearance of pegylated interferon by Kupffer cells limits NK cell activation and therapy response of patients with HBV infection","volume":"13","author":"Nishio","year":"2021","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.isci.2026.117684_bib58","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1111\/cei.13486","article-title":"Combination of pegylated interferon-alpha and nucleos(t)ide analogue treatment enhances the activity of natural killer cells in nucleos(t)ide analogue experienced chronic hepatitis B patients","volume":"202","author":"Pang","year":"2020","journal-title":"Clin. Exp. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib59","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.1067362","article-title":"Functional molecular expression of nature killer cells correlated to HBsAg clearance in HBeAg-positive chronic hepatitis B patients during PEG-IFN \u03b1-2a therapy","volume":"13","author":"Cao","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib60","article-title":"Serum cytokine change profile associated with HBsAg loss during combination therapy with PEG-IFN-\u03b1 in NAs-suppressed chronic hepatitis B patients","volume":"14","author":"Wang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib61","doi-asserted-by":"crossref","first-page":"3527","DOI":"10.3748\/wjg.v25.i27.3527","article-title":"Immune suppression in chronic hepatitis B infection associated liver disease: A review","volume":"25","author":"Li","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2026.117684_bib62","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1128\/JVI.77.1.68-76.2003","article-title":"CD8(+) T cells mediate viral clearance and disease pathogenesis during acute hepatitis B virus infection","volume":"77","author":"Thimme","year":"2003","journal-title":"J. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib63","doi-asserted-by":"crossref","first-page":"881","DOI":"10.3748\/wjg.v28.i9.881","article-title":"Innate and adaptive immune escape mechanisms of hepatitis B virus","volume":"28","author":"Zhao","year":"2022","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/j.isci.2026.117684_bib64","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2015.42","article-title":"T-cell exhaustion in chronic hepatitis B infection: current knowledge and clinical significance","volume":"6","author":"Ye","year":"2015","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.isci.2026.117684_bib65","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1172\/JCI33402","article-title":"Bim-mediated deletion of antigen-specific CD8 T cells in patients unable to control HBV infection","volume":"118","author":"Lopes","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117684_bib66","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-024-54378-9","article-title":"Viral sequence determines HLA-E-restricted T cell recognition of hepatitis B surface antigen","volume":"15","author":"Murugesan","year":"2024","journal-title":"Nat. Commun."},{"key":"10.1016\/j.isci.2026.117684_bib67","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.immuni.2020.04.014","article-title":"Developmental Relationships of Four Exhausted CD8(+) T Cell Subsets Reveals Underlying Transcriptional and Epigenetic Landscape Control Mechanisms","volume":"52","author":"Beltra","year":"2020","journal-title":"Immunity"},{"key":"10.1016\/j.isci.2026.117684_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2021.103464","article-title":"Longitudinal characterization of phenotypic profile of T cells in chronic hepatitis B identifies immune markers associated with HBsAg loss","volume":"69","author":"Xiong","year":"2021","journal-title":"EBioMedicine"},{"key":"10.1016\/j.isci.2026.117684_bib69","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1136\/gutjnl-2020-322404","article-title":"TOX defines the degree of CD8+ T cell dysfunction in distinct phases of chronic HBV infection","volume":"70","author":"Heim","year":"2020","journal-title":"Gut"},{"key":"10.1016\/j.isci.2026.117684_bib70","article-title":"Transcriptional and functional HBV-specific CD8 T cell changes from disease to functional cure in HBeAg-negative chronic hepatitis B","volume":"8","author":"Rossi","year":"2026","journal-title":"JHEP Rep."},{"key":"10.1016\/j.isci.2026.117684_bib71","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1172\/JCI92812","article-title":"Hepatitis B virus-specific T cells associate with viral control upon nucleos(t)ide-analogue therapy discontinuation","volume":"128","author":"Rivino","year":"2018","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.isci.2026.117684_bib72","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1146\/annurev.pathol.1.110304.100230","article-title":"Immunobiology and pathogenesis of viral hepatitis","volume":"1","author":"Guidotti","year":"2006","journal-title":"Annu. Rev. Pathol."},{"key":"10.1016\/j.isci.2026.117684_bib73","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1038\/cmi.2015.25","article-title":"Reversal of B-cell hyperactivation and functional impairment is associated with HBsAg seroconversion in chronic hepatitis B patients","volume":"12","author":"Xu","year":"2015","journal-title":"Cell. Mol. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib74","doi-asserted-by":"crossref","DOI":"10.1080\/07853890.2025.2463569","article-title":"The remodeling of B-cell subsets was correlated with the clearance of hepatitis B antigen during pegylated IFN \u03b1-2a therapy in CHB patients","volume":"57","author":"Tan","year":"2025","journal-title":"Ann. Med."},{"key":"10.1016\/j.isci.2026.117684_bib75","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0242559","article-title":"B cells were related to HBsAg seroconversion in inactive HBsAg carriers following peginterferon therapy","volume":"15","author":"Cao","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.isci.2026.117684_bib76","doi-asserted-by":"crossref","DOI":"10.1080\/22221751.2024.2409350","article-title":"Circulating HBsAg-specific B cells are partially rescued in chronically HBV-infected patients with functional cure","volume":"13","author":"Gu","year":"2024","journal-title":"Emerg. Microbes Infect."},{"key":"10.1016\/j.isci.2026.117684_bib77","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1146\/annurev.me.38.020187.001545","article-title":"IgG subclass deficiencies","volume":"38","author":"Ochs","year":"1987","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.isci.2026.117684_bib78","article-title":"Low Level of Serum Immunoglobulin G Is Beneficial to Clinical Cure Obtained With Pegylated Interferon Therapy in Inactive Surface Antigen Carriers","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib79","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/9069375","article-title":"Clinical Relevance of HLA Gene Variants in HBV Infection","volume":"2016","author":"Wang","year":"2016","journal-title":"J. Immunol. Res."},{"key":"10.1016\/j.isci.2026.117684_bib80","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1099\/vir.0.052167-0","article-title":"An immunodominant HLA-A\u22171101-restricted CD8+ T-cell response targeting hepatitis B surface antigen in chronic hepatitis B patients","volume":"94","author":"Chen","year":"2013","journal-title":"J. Gen. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib81","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1002\/hep.24048","article-title":"Strong influence of human leukocyte antigen (HLA)-DP gene variants on development of persistent chronic hepatitis B virus carriers in the Han Chinese population","volume":"53","author":"Guo","year":"2011","journal-title":"Hepatology"},{"key":"10.1016\/j.isci.2026.117684_bib82","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1016\/j.virusres.2011.10.020","article-title":"The influence of HLA alleles and HBV subgenotyes on the outcomes of HBV infections in Northeast China","volume":"163","author":"Li","year":"2012","journal-title":"Virus Res."},{"key":"10.1016\/j.isci.2026.117684_bib83","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1111\/liv.13405","article-title":"Role of HLA-DP and HLA-DQ on the clearance of hepatitis B virus and the risk of chronic infection in a multiethnic population","volume":"37","author":"Trinks","year":"2017","journal-title":"Liver Int."},{"key":"10.1016\/j.isci.2026.117684_bib84","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1007\/s12016-014-8465-4","article-title":"Cytokine-Mediated Immunopathogenesis of Hepatitis B Virus Infections","volume":"50","author":"Li","year":"2016","journal-title":"Clin. Rev. Allergy Immunol."},{"key":"10.1016\/j.isci.2026.117684_bib85","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jinf.2014.03.003","article-title":"Gene variation in IL10 and susceptibility to chronic hepatitis B","volume":"69","author":"Zhang","year":"2014","journal-title":"J. Infect."},{"key":"10.1016\/j.isci.2026.117684_bib86","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1007\/s15010-010-0075-3","article-title":"A meta-analysis of the relation of polymorphism at sites -1082 and -592 of the IL-10 gene promoter with susceptibility and clearance to persistent hepatitis B virus infection in the Chinese population","volume":"39","author":"Zhang","year":"2011","journal-title":"Infection"},{"key":"10.1016\/j.isci.2026.117684_bib87","doi-asserted-by":"crossref","first-page":"515","DOI":"10.5152\/tjg.2020.181024","article-title":"Interferon gamma gene polymorphisms and chronic hepatitis B infections in an Iranian population","volume":"31","author":"Heidari","year":"2020","journal-title":"Turk. J. Gastroenterol."},{"key":"10.1016\/j.isci.2026.117684_bib88","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/j.cgh.2019.04.044","article-title":"Variants in STAT4 Associated With Cure of Chronic HBV Infection in HBeAg-positive Patients Treated With Pegylated Interferon-alpha","volume":"18","author":"Chen","year":"2020","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib89","doi-asserted-by":"crossref","first-page":"36","DOI":"10.14715\/cmb\/2024.70.12.5","article-title":"Association between extracellular matrix protein 1 (ECM1) gene polymorphisms (rs3834087 and rs3754217) and Hepatitis B Virus evolution in an African cohort","volume":"70","author":"Traore","year":"2025","journal-title":"Cell. Mol. Biol. (Noisy-le-grand)"},{"key":"10.1016\/j.isci.2026.117684_bib90","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s00705-023-05949-6","article-title":"ENPP1 inhibits the transcription activity of the hepatitis B virus pregenomic promoter by upregulating the acetylation of LMNB1","volume":"169","author":"Ma","year":"2024","journal-title":"Arch. Virol."},{"key":"10.1016\/j.isci.2026.117684_bib91","doi-asserted-by":"crossref","DOI":"10.1016\/j.meegid.2020.104663","article-title":"Human genetic susceptibility to hepatitis B virus infection","volume":"87","author":"Xu","year":"2021","journal-title":"Infect. Genet. Evol."},{"key":"10.1016\/j.isci.2026.117684_bib92","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1016\/j.cgh.2023.02.032","article-title":"New Perspectives on Development of Curative Strategies for Chronic Hepatitis B","volume":"21","author":"Feld","year":"2023","journal-title":"Clin. Gastroenterol. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib93","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2025.106214","article-title":"RXR agonist S169 inhibits HBV\/HDV entry in vitro by disrupting KIF4-dependent NTCP trafficking","volume":"240","author":"Gad","year":"2025","journal-title":"Antiviral Res."},{"key":"10.1016\/j.isci.2026.117684_bib94","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41591-025-04049-z","article-title":"Elebsiran and PEG-IFN\u03b1 for chronic hepatitis B infection: a partially randomized, open-label, phase 2 trial","volume":"32","author":"Wong","year":"2026","journal-title":"Nat. Med."},{"key":"10.1016\/j.isci.2026.117684_bib95","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1056\/NEJMoa2405485","article-title":"Xalnesiran with or without an Immunomodulator in Chronic Hepatitis B","volume":"391","author":"Hou","year":"2024","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.isci.2026.117684_bib96","doi-asserted-by":"crossref","first-page":"900","DOI":"10.1016\/j.jhep.2019.06.028","article-title":"Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study","volume":"71","author":"Gane","year":"2019","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib97","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/j.jhep.2024.06.027","article-title":"Phase Ib\/IIa randomized study of heterologous ChAdOx1-HBV\/MVA-HBV therapeutic vaccination (VTP-300) as monotherapy and combined with low-dose nivolumab in virally-suppressed patients with CHB","volume":"81","author":"Tak","year":"2024","journal-title":"J. Hepatol."},{"key":"10.1016\/j.isci.2026.117684_bib98","article-title":"Safety, pharmacodynamics, and antiviral activity of selgantolimod in viremic patients with chronic hepatitis B virus infection","volume":"6","author":"Janssen","year":"2024","journal-title":"JHEP Rep."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030658?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004226030658?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T22:05:55Z","timestamp":1794348355000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004226030658"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":97,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S2589004226030658"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2026.117684","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Viral persistence and immune dysfunction in chronic hepatitis B: Mechanisms of post-treatment antigen asynchrony","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2026.117684","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"117684"}}